Table 1 Clinicopathological characteristics for the study cohort.
From: Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer
Patient ID | Sex | Age | Biopsy | EGFR mutation | BRAF mutation | Co-mutations | ||
|---|---|---|---|---|---|---|---|---|
01 | F | 70 | TB | E746_A750del, T790M | V600E | Class I | Acquired (osimertinib) | Persistent T790M |
02 | F | 71 | TB | E746_A750del, T790M | S605C | Not classified | Initial | TP53 R273H |
03 | M | 61 | TB | L858R | K601E | Class II | Initial | DDR2 R279M |
04 | M | 72 | TB | E746_A750del, T790M | V600E | Class I | Acquired (osimertinib) | loss of T790M |
05 | M | 77 | TB | L861Q | G466A | Class III | Acquired (afatinib) | ERBB2 G815A, TP53 S166* |
06 | M | 66 | TB | L858R, V834L | V600E | Class I | Acquired (osimertinib) | loss of EGFR mutations |
07 | F | 84 | TB | L858R | V600E | Class I | Initial | – |
08 | F | 74 | TB | L858R | G466E | Class III | Acquired (gefitinib) | – |
09 | M | 50 | TB | E746_A750del | V600E | Class I | Acquired (osimertinib) | CCDC6-RET |
10 | F | 67 | TB | L747_P753delinsS | G466E | Class III | Initial | KRAS A59E |
11 | F | 75 | TB | E746_A750del | S605N | Not classified | Initial | – |
12 | F | 61 | LB | E746_A750del, 790M, C797S, C797G | V600E | Class I | Acquired (osimertinib) | TP53 splice |
13 | M | 50 | LB | L747_S752del | K601E | Class II | Acquired (osimertinib) | TP53 R248G |
14 | F | 70 | TB | L858R, T790M, C797S | V600E | Class I | Acquired (osimertinib) | TP53 K120E, BRCA S237Y (VUS) |
15 | M | 52 | TB | L747_A750delinsP T790M, C797G | V600E | Class I | Acquired (osimertinib) | CTNNB1 S37C, ATM R1437K (VUS) |
